久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Shanghai looking to become international hub for medical industry

By CAO CHEN in Shanghai | China Daily | Updated: 2021-04-08 09:51
Share
Share - WeChat
A medical worker demonstrates how to conduct a trial for the development of a messenger ribonucleic acid (mRNA) vaccine against COVID-19. [Photo/Xinhua]

Shanghai Pudong New Area's Zhangjiang National Innovation Demonstration Zone-a key player in China's pharmaceutical industry-has developed interactively with industrial parks across the city to boost the whole industrial chain in the past decade.

Among the collaborations is with the Biomedicine Harbor of the Bay Area with a planned area of 7.74 square kilometers, in Jinshan district, southwestern Shanghai.

Located in Jinshan Industrial Park, the harbor has long been pivotal in fueling commercialization of research results for startups. It accommodated 50 enterprises in biologic preparation, traditional Chinese medicine and medical devices, with an annual output value of 9.57 billion yuan ($1.46 billion) in 2020.

At the heart of the harbor is a 270,000 square meter zone jointly developed by Jinshan Industrial Park and Zhangjiang Hi-Tech Park in 2013 to supplement the limited space for medicine production in Zhangjiang, said Huang Tao, deputy manager of the industrial park in Jinshan, which manages the harbor.

Three zones with manufacturing facilities are now available: one for small and micro-sized biopharmaceutical firms, another targeting precision medicine and cell therapy industries and a third supporting firms in pharmaceutical preparations.

Shanghai-based CARsgen Therapeutics settled within the harbor in 2017, having been attracted by the facilities, which according to Wang Huamao, co-founder and COO of the firm, likely saved four years spent on plant construction.

The company now owns an 8,000 sq m manufacturing base for developing Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T)-a tumor immunotherapy mainly applied to leukemia and lymphoma-and has so far obtained 3 CAR-T official approvals to initiate clinical trials.

Resources in Zhangjiang are underpinning more pharma companies for the city's goal of being a biomedical hub in Asia, as 22 citywide industrial parks centered around Zhangjiang have been established in districts including Jinshan and Fengxian districts and Lingang free trade area in Pudong New Area.

"Zhangjiang has been on the frontline of innovation in the city," said Wu Qing, vice-mayor of Shanghai, at a conference held on March 30.

It's home to 330 national-level R&D institutions, with new ones under development by top domestic universities, such as Tsinghua University, Zhejiang University and Shanghai Jiao Tong University, Wu said.

In terms of biomedicine, which makes up a big chunk of core industries in Zhangjiang, the annual output in the area hit 110 billion yuan in 2020, accounting for 78 percent of the total in the city. The area contributed to a third of Class 1 new drugs developed nationwide-meaning they have never been marketed within or outside China-in 2019.

Large scientific installations in Zhangjiang, covering domains like protein research and translational medicine, have been fostering industry growth.

Financial support is also accessible. The industrial park in Fengxian district, for instance, has received Zhangjiang National Innovation Demonstration Zone Special Funds worth 640 million yuan since 2012.

"It drives innovation and enhances startups' competitiveness on the global stage," said Yuan Fei, general manager of Oriental Beauty Valley, a biotechnology zone in the park dedicated to beauty and healthcare.

Buoyed by the funds, Shanghai RAAS Blood Products based in the valley got two inventions patented in 2017. They are expected to serve more patients with bleeding disorders in the future. The company's revenue soared to 2.58 billion yuan in 2019, an increase of 43.3 percent from 2018.

"The aid alleviates the financial burden faced by these SMEs focusing on R&D but with little or no revenue at the earliest stage," Yuan said.

"The valley will strengthen cooperation with Zhangjiang in innovation projects to serve more firms labs, and innovation platforms," he added.

Talent and industrial resources, two other elements empowering startups, are pooled as well, according to Wu Bo, co-CEO of Shanghai Free Biozone-1 Biotech Industrial Park located in Waigaoqiao free trade zone-another region partnering with Zhangjiang.

"Over 700 biomedical companies from home and abroad have gathered near the park, attracted by the business environment spurred by collaborations with Zhangjiang," Wu said.

The park has also worked with local universities to establish R&D centers for scientific research and data exchanges.

Wu said that up to 4 billion yuan will be added to the park's funds in five years to go toward cooperation with investment institutions in order to boost industrialization.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲国产精品一区二区九九 | 一区二区国产精品 | 亚洲精品久久久久综合91 | 爽死你个放荡粗暴小淫货双女视频 | 欧美日本道免费一区二区三区 | 日本道色 | 国产4tube在线播放 | 国产看片一区二区三区 | 欧美午夜不卡在线观看最新 | 天堂1在线观看 | 免费国产不卡午夜福在线 | 在线观看精品国产 | www.亚洲国产 | 国产综合久久 | 高清欧美一级在线观看 | 色老头一级毛片 | 九色国产在线 | 久久观看午夜精品 | 日本香蕉一区二区三区 | 国产成人啪精品视频免费网 | 一级aaaaa毛片免费视频 | 久草视频福利在线 | 黄色网址在线免费观看 | 欧美国产在线一区 | 日本高清视频免费在线观看 | 女人被男人躁得好爽免费文 | 欧美日韩一区二区三区高清不卡 | 久久久久国产成人精品 | 美女张开腿黄网站免费国产 | 国内成人精品亚洲日本语音 | 欧美亚洲免费久久久 | 亚洲天堂区 | 国内精品一区二区在线观看 | 国产性较精品视频免费 | 日本精品中文字幕有码 | 精品国产一区二区三区在线观看 | 一区二区精品在线 | 亚洲国产日韩欧美一区二区三区 | 国产高清在线精品一区二区 | 午夜专区 | 99久久精品国产片 |